Keytruda combo set to become “standard of care” in kidney cancerAnalysts are predicting that a combination of Merck’s Keytruda and Pfizer’s Inlyta will become the standard of care Share XKeytruda combo set to become “standard of care” in kidney cancerhttps://pharmaphorum.com/news/keytruda-combo-set-to-become-standard-of-care-kidney-cancer/
Bayer takes control of Loxo duo as Lilly closes takeoverBayer has acquired full rights to two drugs partnered with Loxo Oncology, on the same day that the Share XBayer takes control of Loxo duo as Lilly closes takeoverhttps://pharmaphorum.com/news/bayer-control-loxo-duo-lilly-takeover/
Trial could unlock new prostate cancer sales for Pfizer/Astellas’ XtandiPfizer and Astellas’ Xtandi has shown it is effective in men with prostate cancer that has spread but Share XTrial could unlock new prostate cancer sales for Pfizer/Astellas’ Xtandihttps://pharmaphorum.com/news/trial-prostate-cancer-pfizer-astellas-xtandi/
NICE backs Takeda’s Alunbrig in second-line lung cancerNICE has published final draft guidance recommending regular NHS funding in England for Takeda’s Alunbrig (brigatinib), for ALK-positive Share XNICE backs Takeda’s Alunbrig in second-line lung cancerhttps://pharmaphorum.com/news/nice-backs-takedas-alunbrig-in-second-line-lung-cancer/
Bayer/Orion showcase results from prostate cancer challengerBayer and development partner Orion have released detailed results from the trial that will form the backbone of Share XBayer/Orion showcase results from prostate cancer challengerhttps://pharmaphorum.com/news/bayer-orion-showcase-results-from-prostate-cancer-challenger/
AZ’s CEO dismisses “fake news” about his imminent departureAstraZeneca’s CEO Pascal Soriot has dismissed continued rumours about his departure as “fake news” as the company announced Share XAZ’s CEO dismisses “fake news” about his imminent departurehttps://pharmaphorum.com/news/azs-ceo-dismisses-fake-news-about-his-imminent-departure/
Harpoon and Gossamer sneak out IPOs before potential SEC shutdownImmunotherapy specialist Harpoon Therapeutics has joined a group of biotechs that have sneaked out IPOs before another potential Share XHarpoon and Gossamer sneak out IPOs before potential SEC shutdownhttps://pharmaphorum.com/news/harpoon-and-gossamer-sneak-out-ipos-before-potential-sec-shutdown/
Clinigen buys remaining rights to Novartis cancer drugUK pharma Clinigen has bought the remaining rights to Novartis’ cancer drug Proleukin, in a deal worth up Share XClinigen buys remaining rights to Novartis cancer drughttps://pharmaphorum.com/news/clinigen-buys-remaining-rights-to-novartis-cancer-drug/
Merck’s Keytruda gets boost in kidney and head and neck cancerMerck & Co and its cancer immunotherapy Keytruda has gained a double boost in its tussle with rival Share XMerck’s Keytruda gets boost in kidney and head and neck cancerhttps://pharmaphorum.com/news/mercks-keytruda-gets-boost-in-kidney-and-head-and-neck-cancer/
